📊 IKT Key Takeaways
Is Inhibikase Therapeutics, Inc. (IKT) a Good Investment?
Inhibikase is a pre-revenue biopharmaceutical company with zero commercial sales and annual operating losses of $17.8M, burning approximately $12.1M in cash annually. While the balance sheet is strong with $49.6M in cash providing approximately 4 years of runway and minimal debt ($381.8K), the lack of revenue generation, high cash burn rate, and negative returns on equity (-9.8%) indicate substantial execution risk without visible near-term commercialization catalysts.
IKT is deeply unprofitable with minimal revenue and extreme negative margins, but it holds a very strong, cash‑heavy balance sheet with negligible debt and exceptional liquidity, providing a multi‑year runway. The fundamental outlook hinges on curbing cash burn and demonstrating durable revenue traction before profitability is plausible.
Inhibikase Therapeutics, Inc. Key Strengths (IKT)
- Strong balance sheet with $49.6M cash and $167.6M stockholders' equity
- Minimal leverage with only $381.8K long-term debt and 0.00x debt-to-equity ratio
- Excellent liquidity position with 30.14x current ratio providing operational flexibility
- Improving loss trend with diluted EPS improving 57.8% year-over-year
- Cash-rich balance sheet (~$179M) versus low liabilities (~$8.3M)
- Minimal leverage and interest burden
- Very high liquidity (current ratio ~21.7x) and low capex needs
IKT Stock Risks: Inhibikase Therapeutics, Inc. Investment Risks
- Zero revenue generation indicating purely development-stage company with no commercialized products
- Annual cash burn of $12.1M limits runway to approximately 4 years without additional capital raises
- Negative ROE (-9.8%) and ROA (-9.5%) indicate current destruction of shareholder value
- High execution risk dependent on clinical trial success and regulatory approval with no marketed products
- Potential dilution from future capital raises needed to extend runway and fund development
- Persistent large operating losses and highly negative margins
- Sustained cash burn raising dilution/financing risk if spending increases
- Limited revenue base with uncertain scalability and visibility
Key Metrics to Watch
- Clinical trial progress and regulatory milestones for pipeline candidates
- Monthly cash burn rate and cash runway extension
- Net loss trend and path to profitability timeline
- Capital raise announcements and dilution impact on equity
- Operating cash flow (burn/runway)
- Revenue growth and operating margin improvement
Inhibikase Therapeutics, Inc. (IKT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 30.14x current ratio provides a solid financial cushion.
IKT Profit Margin, ROE & Profitability Analysis
IKT vs Healthcare Sector: How Inhibikase Therapeutics, Inc. Compares
How Inhibikase Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inhibikase Therapeutics, Inc. Stock Overvalued? IKT Valuation Analysis 2026
Based on fundamental analysis, Inhibikase Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inhibikase Therapeutics, Inc. Balance Sheet: IKT Debt, Cash & Liquidity
IKT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Inhibikase Therapeutics, Inc.'s revenue has declined by 92% over the 5-year period, indicating business contraction. The most recent EPS of $-1.16 indicates the company is currently unprofitable.
IKT Revenue Growth, EPS Growth & YoY Performance
IKT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$13.7M | $-0.10 |
| Q3 2025 | N/A | -$4.6M | $-0.13 |
| Q2 2025 | N/A | -$4.6M | $-0.11 |
| Q1 2025 | N/A | -$4.6M | $-0.15 |
| Q3 2024 | N/A | -$4.5M | $-0.65 |
| Q2 2024 | N/A | -$4.5M | $-0.66 |
| Q1 2024 | N/A | -$4.5M | $-0.73 |
| Q3 2023 | $7.3K | -$4.5M | $-0.86 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Inhibikase Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
IKT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inhibikase Therapeutics, Inc. (CIK: 0001750149)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IKT
What is the AI rating for IKT?
Inhibikase Therapeutics, Inc. (IKT) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 67% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IKT's key strengths?
Claude: Strong balance sheet with $49.6M cash and $167.6M stockholders' equity. Minimal leverage with only $381.8K long-term debt and 0.00x debt-to-equity ratio. ChatGPT: Cash-rich balance sheet (~$179M) versus low liabilities (~$8.3M). Minimal leverage and interest burden.
What are the risks of investing in IKT?
Claude: Zero revenue generation indicating purely development-stage company with no commercialized products. Annual cash burn of $12.1M limits runway to approximately 4 years without additional capital raises. ChatGPT: Persistent large operating losses and highly negative margins. Sustained cash burn raising dilution/financing risk if spending increases.
What is IKT's revenue and growth?
Inhibikase Therapeutics, Inc. reported revenue of $0.0.
Does IKT pay dividends?
Inhibikase Therapeutics, Inc. does not currently pay dividends.
Where can I find IKT SEC filings?
Official SEC filings for Inhibikase Therapeutics, Inc. (CIK: 0001750149) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IKT's EPS?
Inhibikase Therapeutics, Inc. has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IKT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Inhibikase Therapeutics, Inc. has a C grade with 67% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IKT stock overvalued or undervalued?
Valuation metrics for IKT: ROE of -9.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IKT's AI grade for 2026?
Our dual AI analysis gives Inhibikase Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IKT's free cash flow?
Inhibikase Therapeutics, Inc.'s operating cash flow is $-12.1M, with capital expenditures of $0.0.
How does IKT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -9.8% (avg: 15%), current ratio 30.14 (avg: 2).